AN2 Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
AN2 Therapeutics, Inc. (ANTX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $70.42 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-05-10
- AN2 Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2022-03-31 was $70.42M, a 9.95% decline year-over-year.
- AN2 Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-03-31 was $78.20M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month |
|---|---|
| 2022-03-31 | $70.42M 10-Q · filed 2022-05-10 |
| 2021-03-31 | $78.20M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |